SARS-CoV-2: Survival in COPD phenotypes

M. Pavitt (Billingshurst (West Sussex), United Kingdom), S. Krivinskas (Billingshurst (West Sussex), United Kingdom), J. Congleton (Billingshurst (West Sussex), United Kingdom), S. Hippolyte (Billingshurst (West Sussex), United Kingdom)

Source: Virtual Congress 2021 – Emerging evidence on sub-acute and long COVID-19
Session: Emerging evidence on sub-acute and long COVID-19
Session type: Oral Presentation
Number: 4195

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Pavitt (Billingshurst (West Sussex), United Kingdom), S. Krivinskas (Billingshurst (West Sussex), United Kingdom), J. Congleton (Billingshurst (West Sussex), United Kingdom), S. Hippolyte (Billingshurst (West Sussex), United Kingdom). SARS-CoV-2: Survival in COPD phenotypes. 4195

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
COPD phenotypes
Source: International Congress 2016 – PG1 Asthma and chronic obstructive pulmonary disease
Year: 2016



COPD phenotypes
Source: International Congress 2015 – PG2 Asthma and COPD
Year: 2015




Stability of COPD phenotypes over time
Source: Annual Congress 2012 - Prevalences and characterstics of obstructive airway disease
Year: 2012

Survival characteristics and predictors of mortality in COPD subjects
Source: International Congress 2019 – Long-term evaluation and control of airway diseases
Year: 2019

Identification and analysis of clinical phenotypes in COPD patients: PALOMB Cohort
Source: Virtual Congress 2021 – COPD burden, epidemiology and management
Year: 2021


The distribution of phenotypes in a population of severe COPD
Source: International Congress 2014 – COPD exacerbations
Year: 2014



Survival following pulmonary rehabilitation in COPD patients
Source: Eur Respir J 2004; 24: Suppl. 48, 209s
Year: 2004

Tree years survival rates of COPD patients that hospitalized for acute excecerbation of COPD
Source: International Congress 2014 – Clinical assessment of airway diseases
Year: 2014


Multicomponent indices to predict survival in COPD: the COCOMICS study
Source: Eur Respir J 2013; 42: 323-332
Year: 2013



Prediction models for exacerbations in different COPD patient populations: Results of five large databases
Source: International Congress 2016 – COPD and asthma COPD overlap syndrome (ACOS): novelties in terms of prevalence, risk factors, and prognosis in COPD
Year: 2016

Clinical COPD phenotypes identified by cluster analysis: validation with mortality
Source: Eur Respir J 2012; 40: 495-496
Year: 2012


Metabolic syndrome in COPD patients without cardiovascular comorbidities: Co-existence or a different COPD phenotype?
Source: Annual Congress 2010 - COPD: phenotyping and monitoring
Year: 2010


Frequency of exacerbations in patients with COPD: an analysis of the SPIROMICS cohort
Source: International Congress 2017 – COPD: latest insights into the management of patients
Year: 2017


COPD phenotypes and 5-years mortality risk prediction: PALOMB Cohort
Source: Virtual Congress 2020 – Comorbidities/multimorbidites and mortality in patients with chronic lung diseases
Year: 2020


Survival in COPD patients with hospitalization due to exacerbation
Source: International Congress 2014 – Longitudinal studies of respiratory disease
Year: 2014


Inflammatory markers and COPD phenotypes as predictors of COPD exacerbations
Source: Annual Congress 2013 –Investigating COPD in longitudinal studies
Year: 2013


COPD Phenotypes and Comorbidities
Source: International Congress 2017 – COPD biomarkers
Year: 2017

Heterogeneity inside group D COPD patients: About 827 cases
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016